AltruBio Taiwan Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav
The content above was translated by Ai
Founded Year
2020
Unified Business No.
82948968
Status
Active
Number of Employees
0
Total Paid-in
Capital
25,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AltruBio Inc. is a clinical-stage biotechnology company headquartered in San Francisco with an R&D center in Taipei. They specialize in developing first-in-class immune checkpoint enhancers (ICEs) for immunological and inflammatory diseases, backed by a world-class team with deep expertise in immunology and biologic drug development.
The content above was translated by Ai
